Cryo-Cell International (CCEL) AI Stock Analysis

• Market Cap: $35.04M
• Dividend Yield: 9.09%
• Average Volume (3M): 19.02K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.02
• Revenue Growth: -0.29%
• EPS Growth: 94.56%
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.09
• Shares Outstanding: 8,055,150
• 10 Day Avg. Volume: 7,315
• 30 Day Avg. Volume: 19,023
• PEG Ratio: -1.68
• Price to Book (P/B): -5.33
• Price to Sales (P/S): 2.20
• P/FCF Ratio: 19.54
• Enterprise Value/Market Cap: 1.35
• Enterprise Value/Revenue: 1.49
• Enterprise Value/Gross Profit: 1.93
• Enterprise Value/Ebitda: 9.20
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: $4.50 ▲(2.27% Upside)

Cryo-Cell International's overall stock score reflects significant financial challenges, including declining revenue growth and financial instability. The technical analysis suggests a weak momentum, and the valuation metrics highlight concerns with a negative P/E ratio, although the high dividend yield may provide some appeal. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Cash Flow Generation

The growth in free cash flow indicates improved cash generation, enhancing liquidity and providing financial flexibility for future investments.

Gross Profit Margin

A strong gross profit margin reflects efficient cost management, which can support profitability and competitive pricing strategies over time.

Operational Improvements

Improved EBIT and EBITDA margins suggest better operational efficiency, which could lead to enhanced profitability and business sustainability.

Negative Factors

Revenue Growth Decline

A significant decline in revenue growth indicates challenges in maintaining sales momentum, potentially impacting long-term market position and profitability.

Financial Instability

Negative equity and high leverage pose financial risks, limiting the company's ability to invest in growth and weather economic downturns.

Low Net Profit Margin

A low net profit margin indicates difficulty in converting revenue into profit, which can hinder long-term financial health and shareholder returns.

Cryo-Cell International Business Overview & Revenue Model

Company Description

Cryo-Cell International (CCEL) is a leading biotechnology company specializing in the collection, processing, and storage of umbilical cord blood and tissue stem cells. Founded in 1992, the company operates within the regenerative medicine sector, offering services that allow families to preserve stem cells for potential future medical use. CCEL's core products include private cord blood banking services, which provide parents with the opportunity to store their newborn's stem cells for personal use, as well as public cord blood donations that contribute to research and treatment opportunities in various medical fields.

How the Company Makes Money

Cryo-Cell International generates revenue primarily through its cord blood and tissue banking services. The company charges families an initial fee for the collection and processing of stem cells, followed by annual storage fees for maintaining the samples in their facilities. Additional revenue streams include partnerships with healthcare providers, research institutions, and participation in clinical trials, which may involve collaboration in the development of new treatments leveraging stem cells. Furthermore, Cryo-Cell's public cord blood bank contributes to its reputation and outreach, potentially attracting more private clients. The company's growth and earnings are also bolstered by strategic partnerships and advancements in regenerative medicine, which enhance the perceived value of stem cell storage among consumers.

Cryo-Cell International Financial Statement Overview

Summary

Cryo-Cell International faces challenges in maintaining revenue growth and profitability, with declining revenue and low net profit margins. The balance sheet shows financial instability with high leverage and negative equity, posing potential risks. However, the company demonstrates some strength in cash flow generation, which could support liquidity needs.

Income Statement

Cryo-Cell International's income statement shows a mixed performance. The gross profit margin remains strong at 77% TTM, indicating efficient cost management. However, the net profit margin is low at 1.26% TTM, reflecting challenges in translating revenue into profit. The revenue growth rate has declined significantly by 75.4% TTM, highlighting potential issues in maintaining sales momentum. EBIT and EBITDA margins have improved over the previous year, suggesting some operational improvements.

Balance Sheet

The balance sheet reveals significant financial instability, with a negative stockholders' equity of $-14.83 million TTM, indicating more liabilities than assets. The debt-to-equity ratio is negative, reflecting high leverage and potential financial risk. Return on equity is also negative, suggesting inefficiencies in generating returns from shareholders' investments. The equity ratio is not favorable, pointing to a weak capital structure.

Cash Flow

Cash flow analysis shows some positive trends, with a 6.7% growth in free cash flow TTM, indicating improved cash generation. The operating cash flow to net income ratio is 0.34 TTM, suggesting moderate cash conversion efficiency. The free cash flow to net income ratio is high at 0.95 TTM, reflecting strong cash flow relative to net income, which is a positive sign for liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	31.75M	31.99M	31.34M	30.34M	28.88M	31.15M
Gross Profit	24.47M	24.04M	22.90M	21.54M	19.90M	21.49M
EBITDA	5.15M	1.42M	-10.42M	6.65M	5.32M	7.22M
Net Income	399.61K	402.10K	-9.52M	2.77M	2.08M	3.62M
Balance Sheet
Total Assets	63.17M	64.68M	61.22M	64.89M	60.66M	46.20M
Cash, Cash Equivalents and Short-Term Investments	3.22M	3.50M	980.25K	1.72M	8.34M	10.45M
Total Debt	4.21M	12.93M	10.90M	11.61M	2.82M	6.24M
Total Liabilities	78.00M	77.89M	72.25M	66.41M	56.48M	48.87M
Stockholders Equity	-14.83M	-13.22M	-11.03M	-1.52M	4.18M	-2.67M
Cash Flow
Free Cash Flow	6.05M	3.61M	1.28M	-8.60M	974.92K	8.02M
Operating Cash Flow	6.35M	6.01M	8.92M	8.57M	7.93M	8.47M
Investing Cash Flow	-1.80M	-4.88M	-8.14M	-15.28M	-6.95M	357.49K
Financing Cash Flow	-4.49M	-979.12K	-2.07M	147.86K	-3.07M	-5.00M

Cryo-Cell International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Negative. The current price of 4.4 is below the 20-day moving average (MA) of 4.48, below the 50-day MA of 4.56, and below the 200-day MA of 5.43, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 44.71 is Neutral, neither overbought nor oversold. The STOCH value of 42.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCEL.

Cryo-Cell International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DCGO	―	$105.63M	―	-5.98%	―	-41.31%	-163.08%
AMS	―	$14.39M	-5.98	-9.49%	―	26.61%	-156.30%
PIII	―	$63.54M	-0.18	-138.17%	―	4.20%	-54.16%
CCEL	―	$35.04M	-73.48	―	9.09%	-0.29%	94.56%
CCM	―	$23.01M	-1.02	―	―	-22.38%	56.66%
MODVQ	―	$1.44M	―	―	―	-0.70%	-2.38%

Cryo-Cell International Corporate Events

Cryo-Cell International Amends Credit Agreement with Susser Bank

Cryo-Cell International, Inc. announced a Fifth Amendment to its Credit Agreement with Susser Bank on October 18, 2025. This amendment includes the addition of its subsidiary, Celle Corp., as a guarantor, an extension of the maturity dates for its revolving credit and term loans, and a revision of the revolving credit commitment and applicable margins. The revolving credit commitment was reduced to $8,000,000, and the maturity dates were extended to October 18, 2027, for the revolving credit and July 29, 2032, for the term loan. These changes are expected to impact the company’s financial flexibility and operational planning.

The most recent analyst rating on (CCEL) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.

Cryo-Cell Schedules 2025 Annual Stockholders Meeting

Cryo-Cell International has scheduled its 2025 Annual Meeting of Stockholders for October 21, 2025, with a record date of September 15, 2025, for determining eligible stockholders. Stockholders must submit notices for business or director nominations within ten days of the public disclosure date, September 10, 2025, as per the company’s bylaws.

The most recent analyst rating on (CCEL) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.